论文部分内容阅读
目的:分析研究利拉鲁肽联合二甲双胍治疗2型糖尿病的临床疗效。方法:选取2013年12月至2014年12月在本院进行治疗的2型糖尿病患者80例作为本次观察对象,按照不同的治疗方式将80例患者分成对照组和实验组,每组40例;对照组予以二甲双胍进行治疗,实验组予以利拉鲁肽联合二甲双胍进行治疗;治疗后,对比分析两组患者治疗前后的胰岛素敏感指数、空腹血糖以、餐后2h血糖指标以及效果。结果:实验组患者治疗后的胰岛素敏感指数以及血糖指标的改善程度明显优于对照组患者(P<0.05);实验组患者的治疗有效率为97.50%显著高于对照组患者的82.50%(P<0.05),以上内容组间差异显著,具有统计学意义。结论:临床上采用利拉鲁肽联合二甲双胍治疗2型糖尿病,对患者的胰岛素敏感指数以及血糖指标具有较大的改善作用,治疗效果显著,安全性高。
Objective: To analyze the clinical efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus. Methods: Eighty patients with type 2 diabetes who were treated in our hospital from December 2013 to December 2014 were selected as the observation object. According to different treatment methods, 80 patients were divided into control group and experimental group, 40 cases in each group ; The control group was treated with metformin, the experimental group was treated with liraglutide combined with metformin; after treatment, the two groups of patients before and after treatment of insulin sensitivity index, fasting blood glucose, 2h postprandial blood glucose indicators and the effect. Results: The insulin sensitivity index and the improvement of glycemic index in the experimental group were significantly better than those in the control group (P <0.05). The effective rate of the experimental group was 97.50%, which was significantly higher than that of the control group (P <0.05), the above differences between the groups were significant and statistically significant. Conclusion: The clinical use of liraglutide combined with metformin in the treatment of type 2 diabetes patients with insulin sensitivity index and blood glucose indicators have a greater improvement, the treatment effect is significant and safe.